PTPRG

Summary

PTPRG (protein tyrosine phosphatase receptor type G, HGNC:9671) is a protein-coding gene on chromosome 3p14.2, encoding Receptor-type tyrosine-protein phosphatase gamma (P23470). Possesses tyrosine phosphatase activity.

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and two tandem intracytoplasmic catalytic domains, and thus represents a receptor-type PTP. The extracellular region of this PTP contains a carbonic anhydrase-like (CAH) domain, which is also found in the extracellular region of PTPRBETA/ZETA. This gene is located in a chromosomal region that is frequently deleted in renal cell carcinoma and lung carcinoma, thus is thought to be a candidate tumor suppressor gene.

Source: NCBI Gene 5793 — RefSeq curated summary.

At a glance

• GWAS associations: 30
• Clinical variants (ClinVar): 305 total
• Druggable target: yes
• MANE Select transcript: NM_002841

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9671
Approved symbol	PTPRG
Name	protein tyrosine phosphatase receptor type G
Location	3p14.2
Locus type	gene with protein product
Status	Approved
Aliases	RPTPG
Ensembl gene	ENSG00000144724
Ensembl biotype	protein_coding
OMIM	176886
Entrez	5793

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 4 protein_coding_CDS_not_defined, 2 protein_coding, 1 retained_intron

ENST00000295874, ENST00000468576, ENST00000474889, ENST00000475012, ENST00000475527, ENST00000485215, ENST00000495879

RefSeq mRNA: 2 — MANE Select: NM_002841 NM_001375471, NM_002841

CCDS: CCDS2895, CCDS93303

Canonical transcript exons

ENST00000474889 — 30 exons

Exon	Start	End
ENSE00001322515	61989625	61989804
ENSE00001328874	62231225	62231311
ENSE00001619342	62167971	62168163
ENSE00001629977	62157067	62157224
ENSE00001658058	62003349	62003497
ENSE00001667764	62078163	62078258
ENSE00001741021	62191469	62191653
ENSE00001757754	62201505	62201554
ENSE00001775061	62195062	62195170
ENSE00001796386	62203173	62203950
ENSE00001802413	62132602	62132668
ENSE00001860710	62293161	62297609
ENSE00003468693	62275873	62275966
ENSE00003489585	62269035	62269169
ENSE00003517132	62272946	62273081
ENSE00003528408	62281563	62281709
ENSE00003528818	62255124	62255215
ENSE00003551479	62282727	62282869
ENSE00003565836	62218851	62218983
ENSE00003587902	62243807	62243898
ENSE00003595345	62273698	62273844
ENSE00003599516	62262798	62262894
ENSE00003611914	62267685	62267819
ENSE00003620977	62292421	62292556
ENSE00003631726	62276972	62277048
ENSE00003651076	62267410	62267492
ENSE00003656021	61748878	61748982
ENSE00003679596	62271383	62271555
ENSE00003686477	62277551	62277679
ENSE00003849298	61561571	61562372

Expression profiles

Bgee: expression breadth ubiquitous, 261 present calls, max score 94.90.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 41.7025 / max 503.0031, expressed in 1464 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
37083	27.6726	1456
37085	7.1067	1109
37084	3.5866	1013
37082	1.6710	742
37081	0.6937	359
37086	0.4564	184
37106	0.4017	133
37107	0.0884	39
37080	0.0255	7

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	94.90	gold quality
lower lobe of lung	UBERON:0008949	94.65	gold quality
caput epididymis	UBERON:0004358	93.65	gold quality
synovial joint	UBERON:0002217	92.60	gold quality
buccal mucosa cell	CL:0002336	92.45	gold quality
oocyte	CL:0000023	90.49	gold quality
pericardium	UBERON:0002407	90.44	gold quality
corpus epididymis	UBERON:0004359	90.34	gold quality
urethra	UBERON:0000057	90.29	gold quality
tendon	UBERON:0000043	90.20	gold quality
stromal cell of endometrium	CL:0002255	89.95	gold quality
popliteal artery	UBERON:0002250	89.81	gold quality
choroid plexus epithelium	UBERON:0003911	89.79	gold quality
tibial artery	UBERON:0007610	89.79	gold quality
sural nerve	UBERON:0015488	89.55	gold quality
descending thoracic aorta	UBERON:0002345	89.44	gold quality
aorta	UBERON:0000947	89.20	gold quality
right lung	UBERON:0002167	88.82	gold quality
ventricular zone	UBERON:0003053	88.51	gold quality
colonic epithelium	UBERON:0000397	88.43	gold quality
thoracic aorta	UBERON:0001515	88.39	gold quality
secondary oocyte	CL:0000655	88.33	gold quality
seminal vesicle	UBERON:0000998	88.19	gold quality
ascending aorta	UBERON:0001496	88.11	gold quality
cauda epididymis	UBERON:0004360	88.07	gold quality
left coronary artery	UBERON:0001626	87.90	gold quality
pigmented layer of retina	UBERON:0001782	87.86	gold quality
retina	UBERON:0000966	87.84	gold quality
renal medulla	UBERON:0000362	87.59	gold quality
coronary artery	UBERON:0001621	87.50	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	2357.66
E-GEOD-180759	yes	2254.46
E-CURD-119	yes	35.40
E-ANND-3	yes	27.06
E-GEOD-81608	yes	7.55
E-MTAB-10137	yes	3.97
E-CURD-112	yes	3.89
E-ANND-2	no	5463.97

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTCF, ESR1

miRNA regulators (miRDB)

192 targeting PTPRG, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488

Literature-anchored findings (GeneRIF, showing 36)

• both estradiol-17beta and zeranol regulate PTPgamma expression in human breast; epithelial-stromal cell interaction is important in regulation of PTPgamma expression by estrogenically active agents (PMID:11859871)
• Estrogenic down-regulation of protein tyrosine phosphatase gamma (PTP gamma) in human breast is associated with estrogen receptor alpha. (PMID:12553013)
• PTPgamma may function as an important modulator in regulating the process of tumorigenesis in human breast. (PMID:14676845)
• Promoter hypermethylation of PTPRG is associated with cutaneous T-cell lymphoma (PMID:15897551)
• Significant difference exists in methylation of gene PTPRG between primary tumor and metastatic lymph nodes of gastric cancer. (PMID:17963294)
• There were significant differences of PTPRG gene methylation and PTPRG mRNA expression between gastric primary cancer and lymph node metastases. (PMID:18646686)
• PTPRG may contribute to tumorigenesis. (PMID:18829573)
• findings implicate PTPRG, PTPRZ and CNTNs as a group of receptors and ligands involved in the manifold recognition events that underlie the construction of neural networks (PMID:20133774)
• PTPRG inhibited breast tumor formation in vivo; PTPRG may up-regulate p21(cip) and p27(kip) proteins through the ERK1/2 pathway. (PMID:20651337)
• Downregulation of Protein tyrosine phosphatase receptor type {gamma} is associated with chronic myeloid leukemia. (PMID:20959494)
• Tumor-specific methylation of the first intron of the receptor protein-tyrosine phosphatase gamma gene was found in both sporadic and Lynch syndrome colorectal cancers. (PMID:21150880)
• found that the RPTP-gamma, RPTP-gamma(V948I, S970T) and RPTP-gamma(C858S, S970T) proteins could be stored at 193 K in their respective crystallization buffers without affecting crystallization or crystal quality (PMID:21795790)
• Our results showed that there was no significant association between any of five reported SNPs of TCF4 and PTPRG genes and the occurrence of Fuchs’ endothelial dystrophy; only rs7640737 in PTPRG showed an increased risk for corneal dystrophy. (PMID:23758498)
• PTPRG expression induces dephosphorylation of ERK, a downstream RAS target that may be critical for mutant RAS-induced cell growth. (PMID:24496747)
• Mutations in PDGFRB cause infantile myofibromatosis while a mutation in PTPRG may act as an aggravating factor. (PMID:25158255)
• Germline polymorphisms in PTPRG gene is associated with lung adenocarcinoma. (PMID:25196286)
• SNPs in PTPRG were not associated with FCD in Caucasians. (PMID:25299301)
• PTPRG is a JAK2 phosphatase that negatively regulates leukocyte integrin beta2 activation. (PMID:25624455)
• Results demonstrate that PTPRG plasmatic form (sPTPRG) represent a novel candidate protein biomarker in plasma whose increased expression is associated to hepatocyte damage. (PMID:25775014)
• family-based GWAS of imputed SNPs revealed novel genomic variants in (or near) PTPRG, OSBPL6, and PDCL3 that influence risk for Alzheimer’s Disease. rs7609954 in the gene PTPRG, rs1347297 in the gene OSBPL6, and rs1513625 near PDCL3. In addition, rs72953347 in OSBPL6 and two SNPs in the gene CDKAL1 showed marginally significant association with LOAD (rs10456232, P-value=4.76 x 10-7; rs62400067, P-value=3.54 x 10-7). (PMID:26830138)
• miR-19b inhibits PTPRG expression to promote tumorigenesis in human breast cancer (PMID:27602768)
• Co-localization experiments performed with both anti-PTPRG antibodies identified the presence of isoforms and confirmed protein downregulation at diagnosis in the Philadelphia-positive myeloid lineage (including CD34+/CD38bright/dim cells). (PMID:28637510)
• PTPRG and FGFR1 interact and colocalize at the plasma membrane where PTPRG directly dephosphorylates activated FGFR1. (PMID:29371290)
• OPCML and PTPRG, coordinate to repress AXL-dependent oncogenic signalling. (PMID:29907679)
• cMras was a sponge of miRNA-567 and released its direct target, PTPRG. cMras overexpression decreased miR-567 expression and subsequently increased PTPRG expression, while increased miRNA-567 expression blocked the effects induced by cMras. Moreover, PTPRG was downregulated in lung adenocarcinoma and patients with low PTPRG expression exhibited significantly poor prognosis. (PMID:31012177)
• Regulative Loop between beta-catenin and Protein Tyrosine Receptor Type gamma in Chronic Myeloid Leukemia. (PMID:32225105)
• Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar. (PMID:32700424)
• PTPRG is an ischemia risk locus essential for HCO3(-)-dependent regulation of endothelial function and tissue perfusion. (PMID:32955439)
• Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients. (PMID:33893334)
• Activation of Protein Tyrosine Phosphatase Receptor Type gamma Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells. (PMID:34162728)
• Long Noncoding RNAs PTPRG Antisense RNA 1 Targets Cyclin D1 to Facilitate Cell Proliferation in Lung Adenocarcinoma. (PMID:34767727)
• Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors. (PMID:34906644)
• A Comprehensive Review of Receptor-Type Tyrosine-Protein Phosphatase Gamma (PTPRG) Role in Health and Non-Neoplastic Disease. (PMID:35053232)
• Loss of RPTPgamma primes breast tissue for acid extrusion, promotes malignant transformation and results in early tumour recurrence and shortened survival. (PMID:35821297)
• Gene Expression Landscape of Chronic Myeloid Leukemia K562 Cells Overexpressing the Tumor Suppressor Gene PTPRG. (PMID:36077295)
• The EGFR phosphatase RPTPgamma is a redox-regulated suppressor of promigratory signaling. (PMID:36988334)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ptprga	ENSDARG00000045006
mus_musculus	Ptprg	ENSMUSG00000121513
rattus_norvegicus	Ptprg	ENSRNOG00000009419

Paralogs (35): PTPRN (ENSG00000054356), PTPRU (ENSG00000060656), PTPN3 (ENSG00000070159), PTPN21 (ENSG00000070778), PTPN18 (ENSG00000072135), PTPN23 (ENSG00000076201), PTPRH (ENSG00000080031), PTPRC (ENSG00000081237), PTPN4 (ENSG00000088179), PTPRS (ENSG00000105426), PTPRZ1 (ENSG00000106278), PTPN5 (ENSG00000110786), PTPN6 (ENSG00000111679), PTPRB (ENSG00000127329), PTPN12 (ENSG00000127947), PTPRE (ENSG00000132334), PTPRA (ENSG00000132670), PTPN22 (ENSG00000134242), PTPRF (ENSG00000142949), PTPN7 (ENSG00000143851), PTPRJ (ENSG00000149177), PTPRO (ENSG00000151490), PTPN14 (ENSG00000152104), PTPRK (ENSG00000152894), PTPRR (ENSG00000153233), PTPRD (ENSG00000153707), PTPRN2 (ENSG00000155093), PTPN13 (ENSG00000163629), PTPN9 (ENSG00000169410), PTPRM (ENSG00000173482), PTPN2 (ENSG00000175354), PTPN11 (ENSG00000179295), PTPRT (ENSG00000196090), PTPN1 (ENSG00000196396), PTPN20 (ENSG00000204179)

Protein

Protein identifiers

Receptor-type tyrosine-protein phosphatase gamma — P23470 (reviewed: P23470)

All UniProt accessions (1): P23470

UniProt curated annotations — full annotation on UniProt →

Function. Possesses tyrosine phosphatase activity.

Subunit / interactions. Monomer; active form. Homodimer; inactive form. Interacts with CNTN3, CNTN4, CNTN5 and CNTN6.

Subcellular location. Membrane.

Tissue specificity. Found in a variety of tissues.

Similarity. Belongs to the protein-tyrosine phosphatase family. Receptor class 5 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P23470-1	1	yes
P23470-2	2

RefSeq proteins (2): NP_001362400, NP_002832* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000242	PTP_cat	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR001148	CA_dom	Domain
IPR003595	Tyr_Pase_cat	Domain
IPR003961	FN3_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR016130	Tyr_Pase_AS	Active_site
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036398	CA_dom_sf	Homologous_superfamily
IPR041887	Alpha_CARP_receptor-type	Domain
IPR050348	Protein-Tyr_Phosphatase	Family

Pfam: PF00041, PF00102, PF00194

Enzyme classification (BRENDA):

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (119 total): strand 41, helix 30, glycosylation site 8, sequence conflict 6, compositionally biased region 4, mutagenesis site 4, domain 4, turn 4, binding site 3, sequence variant 3, region of interest 2, topological domain 2, signal peptide 1, chain 1, active site 1, site 1, modified residue 1, disulfide bond 1, transmembrane region 1, splice variant 1

Structure

Experimental structures (PDB)

20 structures.

PDB	Method	Resolution (Å)
2H4V	X-RAY DIFFRACTION	1.55
2PBN	X-RAY DIFFRACTION	1.7
3JXH	X-RAY DIFFRACTION	1.7
3QCD	X-RAY DIFFRACTION	1.8
3QCG	X-RAY DIFFRACTION	2.05
3QCK	X-RAY DIFFRACTION	2.05
3QCB	X-RAY DIFFRACTION	2.1
3QCC	X-RAY DIFFRACTION	2.1
3QCE	X-RAY DIFFRACTION	2.1
3QCJ	X-RAY DIFFRACTION	2.26
3QCI	X-RAY DIFFRACTION	2.27
2NLK	X-RAY DIFFRACTION	2.4
3QCH	X-RAY DIFFRACTION	2.4
3QCL	X-RAY DIFFRACTION	2.4
3QCM	X-RAY DIFFRACTION	2.4
3QCN	X-RAY DIFFRACTION	2.41
3QCF	X-RAY DIFFRACTION	2.5
8XQD	X-RAY DIFFRACTION	2.55
2HY3	X-RAY DIFFRACTION	2.6
5E5R	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P23470-F1	72.76	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 1060 (phosphocysteine intermediate); 1351 (ancestral active site)

Ligand- & substrate-binding residues (3): 1028; 1060–1066; 1104

Post-translational modifications (1): 1182

Disulfide bonds (1): 78–261

Glycosylation sites (8): 109, 113, 156, 359, 444, 619, 631, 722

Mutagenesis-validated functional residues (4):

Position	Phenotype
958	loss of dimerization; when associated with e-960.
960	loss of dimerization; when associated with e-958.
1305	loss of dimerization; when associated with k-1306.
1306	loss of dimerization; when associated with k-1305.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 292 (showing top): BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP, RRAGTTGT_UNKNOWN, HNF3ALPHA_Q6, HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN, PAX4_01, GOZGIT_ESR1_TARGETS_DN, GOBP_REGULATION_OF_EPITHELIAL_CELL_MIGRATION, GOBP_NEUROGENESIS, CHX10_01, AATGGAG_MIR136, GOBP_AMEBOIDAL_TYPE_CELL_MIGRATION, AGGCACT_MIR5153P, DING_LUNG_CANCER_BY_MUTATION_RATE, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_CELL_CELL_ADHESION

GO Biological Process (7): signal transduction (GO:0007165), cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169), negative regulation of epithelial cell migration (GO:0010633), negative regulation of neuron projection development (GO:0010977), neuron projection development (GO:0031175), protein dephosphorylation (GO:0006470), dephosphorylation (GO:0016311)

GO Molecular Function (6): protein tyrosine phosphatase activity (GO:0004725), transmembrane receptor protein tyrosine phosphatase activity (GO:0005001), identical protein binding (GO:0042802), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (4): plasma membrane (GO:0005886), extracellular exosome (GO:0070062), obsolete extracellular space (GO:0005615), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
enzyme-linked receptor protein signaling pathway	1
epithelial cell migration	1
regulation of epithelial cell migration	1
negative regulation of cell migration	1
negative regulation of multicellular organismal process	1
regulation of neuron projection development	1
neuron projection development	1
negative regulation of cell projection organization	1
neuron development	1
plasma membrane bounded cell projection organization	1
dephosphorylation	1
protein modification process	1
phosphate-containing compound metabolic process	1
phosphoprotein phosphatase activity	1
protein tyrosine phosphatase activity	1
transmembrane receptor protein phosphatase activity	1
protein binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
membrane	1
cell periphery	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2318 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPRG	CNTN4	Q8IWV2	811
PTPRG	CNTN3	Q9P232	772
PTPRG	PTS	Q03393	764
PTPRG	CNTN6	Q9UQ52	692
PTPRG	FHIT	P49789	692
PTPRG	PTPN13	Q12923	633
PTPRG	DIRC1	Q969H9	547
PTPRG	EGFR	P00533	528
PTPRG	LRIG1	Q96JA1	506
PTPRG	HSPBAP1	Q96EW2	494
PTPRG	CNTN5	O94779	455
PTPRG	RNF139	Q8WU17	444
PTPRG	PTPRZ1	P23471	429
PTPRG	SLC49A4	Q96SL1	424
PTPRG	PTPN14	Q15678	418

IntAct

193 interactions, top by confidence:

A	B	Type	Score
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
PTPRG	PTPRG	psi-mi:“MI:0407”(direct interaction)	0.660
PTPRG	PTPRG	psi-mi:“MI:0914”(association)	0.660
PDGFRB	PIK3R2	psi-mi:“MI:0914”(association)	0.610
PTPRG	CTNNB1	psi-mi:“MI:0915”(physical association)	0.610
PTPRG	EGFR	psi-mi:“MI:0915”(physical association)	0.570
EGFR	PTPRG	psi-mi:“MI:0915”(physical association)	0.570
PACS1	PTPRG	psi-mi:“MI:0915”(physical association)	0.530
FYTTD1	UBA6	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
FCN1	POTEF	psi-mi:“MI:0914”(association)	0.530
GJB7	PALM3	psi-mi:“MI:0914”(association)	0.530
LGALS1	PODXL	psi-mi:“MI:0914”(association)	0.530
CCNL2	ZBTB43	psi-mi:“MI:0914”(association)	0.530
TMEM185A	TSPAN6	psi-mi:“MI:0914”(association)	0.530
SERPINA12	TSPAN6	psi-mi:“MI:0914”(association)	0.530
LGALS3	PODXL	psi-mi:“MI:0914”(association)	0.530
LGALS1	LAMA5	psi-mi:“MI:0914”(association)	0.530
PTPRG	SNX27	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRG	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRG	PDZD2	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRG	DLG1	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRG	DLG4	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRG	MAGI3	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (131): PTPRG (Affinity Capture-MS), PTPRG (Affinity Capture-MS), PTPRG (Affinity Capture-MS), PTPRG (Affinity Capture-MS), PTPRG (Affinity Capture-MS), PTPRG (Proximity Label-MS), PTPRG (Proximity Label-MS), SEC24A (Proximity Label-MS), FCHO2 (Proximity Label-MS), CEP89 (Proximity Label-MS), CDC42BPB (Proximity Label-MS), FAM129B (Proximity Label-MS), PSD3 (Proximity Label-MS), PALM (Proximity Label-MS), CASKIN2 (Proximity Label-MS)

ESM2 similar proteins: A1XQX3, A1XQY0, A1XQY3, A2ALI5, A6QLD2, B5X216, D0PRN4, E9PUN2, O35181, O75151, O94933, O94991, P0C7U0, P15379, P23470, P49415, P56975, P58401, P80560, Q05909, Q3SXY7, Q3UH99, Q3V1G4, Q4W8E7, Q58EG3, Q5EGE1, Q5R3F8, Q5R5B8, Q63376, Q63475, Q68BL8, Q68FM6, Q6QD51, Q6ZSJ9, Q76KF0, Q80Z10, Q810B7, Q810B9, Q8AXP2, Q8C8T7

Diamond homologs: A0A6I8TCE0, A1L1L3, A2ALK8, A4IFW2, B0V2N1, B0X4T2, B1AUH1, B2GV87, B2RU80, B3DK56, B9EKR1, E9Q0N2, E9Q612, F1NWE3, G5EC24, G5EGJ9, H2KZM6, O02695, O08617, O13016, O35239, O55082, P06800, P16620, P17706, P18031, P18052, P18433, P20417, P23467, P23468, P23469, P23470, P23471, P26045, P28191, P29074, P29350, P29351, P29352

SIGNOR signaling

49 interactions.

A	Effect	B	Mechanism
PTPRG	“down-regulates activity”	JAK2	dephosphorylation
PTPRG	“down-regulates activity”	ITGB2
PTPRG	“down-regulates activity”	ITGAL
PTPRG	“down-regulates activity”	PTPRG	binding
PTPRG	“down-regulates activity”	ABL1	dephosphorylation
PTPRG	“up-regulates activity”	BLNK	dephosphorylation
PTPRG	“down-regulates activity”	BMX	dephosphorylation
PTPRG	“down-regulates activity”	BTK	dephosphorylation
PTPRG	“down-regulates activity”	CDK2	dephosphorylation
PTPRG	“down-regulates activity”	CTTN	dephosphorylation
PTPRG	“down-regulates activity”	DAB1	dephosphorylation
PTPRG	“up-regulates activity”	DOK2	dephosphorylation
PTPRG	“down-regulates activity”	EGFR	dephosphorylation
PTPRG	“up-regulates activity”	EGFR	dephosphorylation
PTPRG	“up-regulates activity”	ERBB2	dephosphorylation
PTPRG	“up-regulates activity”	GRIN2B	dephosphorylation
PTPRG	“up-regulates activity”	INSR	dephosphorylation
PTPRG	“down-regulates activity”	ITGB1	dephosphorylation
PTPRG	“down-regulates activity”	KDR	dephosphorylation
PTPRG	“down-regulates activity”	KIT	dephosphorylation
PTPRG	“down-regulates activity”	LIMK1	dephosphorylation
PTPRG	“down-regulates activity”	MET	dephosphorylation
PTPRG	“up-regulates activity”	PDGFRA	dephosphorylation
PTPRG	“down-regulates activity”	PDGFRB	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 161 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Ras activation upon Ca2+ influx through NMDA receptor	6	30.3×	3e-06
Long-term potentiation	7	29.5×	4e-07
Unblocking of NMDA receptors, glutamate binding and activation	6	28.9×	4e-06
Negative regulation of NMDA receptor-mediated neuronal transmission	6	28.9×	4e-06
GAB1 signalosome	5	28.1×	4e-05
Assembly and cell surface presentation of NMDA receptors	10	22.5×	5e-09
Neurexins and neuroligins	11	19.2×	5e-09
Signaling by ERBB2	5	15.3×	7e-04

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	11	41.5×	1e-12
protein localization to synapse	6	29.8×	7e-06
receptor clustering	7	28.4×	2e-06
regulation of postsynaptic membrane neurotransmitter receptor levels	7	22.5×	5e-06
T cell costimulation	8	19.4×	2e-06
peptidyl-tyrosine phosphorylation	5	13.7×	2e-03
symbiont entry into host cell	5	13.0×	3e-03
epidermal growth factor receptor signaling pathway	8	12.9×	3e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

305 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	228
Likely benign	27
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

7980 predictions. Top by Δscore:

Variant	Effect	Δscore
3:61622461:A:G	acceptor_gain	1.0000
3:61700689:G:GT	donor_gain	1.0000
3:61700690:A:T	donor_gain	1.0000
3:61734629:G:GT	donor_gain	1.0000
3:61748875:CA:C	acceptor_loss	1.0000
3:61748876:A:AG	acceptor_gain	1.0000
3:61748876:AGC:A	acceptor_gain	1.0000
3:61748877:G:GA	acceptor_gain	1.0000
3:61748877:GC:G	acceptor_gain	1.0000
3:61748877:GCG:G	acceptor_gain	1.0000
3:61748979:TCTGG:T	donor_loss	1.0000
3:61748980:CTGG:C	donor_loss	1.0000
3:61748981:TGGTA:T	donor_loss	1.0000
3:61748982:GGTAA:G	donor_loss	1.0000
3:61748983:G:C	donor_loss	1.0000
3:61748983:G:GG	donor_gain	1.0000
3:61748984:T:A	donor_loss	1.0000
3:61974867:GCT:G	donor_gain	1.0000
3:61989800:AACAG:A	donor_loss	1.0000
3:61989801:ACAG:A	donor_loss	1.0000
3:61989802:CAG:C	donor_loss	1.0000
3:61989803:AG:A	donor_loss	1.0000
3:61989804:GGTA:G	donor_loss	1.0000
3:61989805:G:A	donor_loss	1.0000
3:61989806:T:A	donor_loss	1.0000
3:62003334:A:AG	acceptor_gain	1.0000
3:62003334:ATTT:A	acceptor_gain	1.0000
3:62003335:T:G	acceptor_gain	1.0000
3:62003337:T:TA	acceptor_gain	1.0000
3:62003343:A:AG	acceptor_gain	1.0000

AlphaMissense

9606 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:62191534:T:A	W367R	1.000
3:62191534:T:C	W367R	1.000
3:62191536:G:C	W367C	1.000
3:62191536:G:T	W367C	1.000
3:62195122:T:A	C427S	1.000
3:62195122:T:C	C427R	1.000
3:62195123:G:C	C427S	1.000
3:62195124:T:G	C427W	1.000
3:62267488:T:A	V912D	1.000
3:62267751:T:A	W936R	1.000
3:62267751:T:C	W936R	1.000
3:62271449:T:A	W1026R	1.000
3:62271449:T:C	W1026R	1.000
3:62275944:C:A	N1179K	1.000
3:62275944:C:G	N1179K	1.000
3:62277035:C:A	A1208D	1.000
3:62277591:C:A	P1226H	1.000
3:62277591:C:G	P1226R	1.000
3:62277617:T:A	W1235R	1.000
3:62277617:T:C	W1235R	1.000
3:62277618:G:C	W1235S	1.000
3:62277619:G:C	W1235C	1.000
3:62277619:G:T	W1235C	1.000
3:62277621:G:C	R1236P	1.000
3:62277629:T:A	W1239R	1.000
3:62277629:T:C	W1239R	1.000
3:62281584:T:A	W1263R	1.000
3:62281584:T:C	W1263R	1.000
3:62281587:C:T	P1264S	1.000
3:62281588:C:A	P1264Q	1.000

dbSNP variants (sampled 300 via entrez): RS1000002833 (3:61908431 A>G), RS1000004826 (3:61996559 G>A), RS1000014246 (3:61793381 G>T), RS1000016007 (3:61942157 A>C,G,T), RS1000020457 (3:62223272 G>A), RS1000020987 (3:62087864 T>C), RS1000021116 (3:62242400 C>G), RS1000023551 (3:61904840 T>G), RS1000032745 (3:61570949 C>T), RS1000038430 (3:61606610 A>C), RS1000040360 (3:62043586 T>A), RS1000040401 (3:61834230 G>T), RS1000041463 (3:61863608 C>A), RS1000043999 (3:61579730 G>T), RS1000046364 (3:62217210 T>C)

Disease associations

OMIM: gene MIM:176886 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

30 associations (top):

Study	Trait	p-value
GCST000452_9	QT interval	8.000000e-07
GCST000578_5	Major depressive disorder	4.000000e-06
GCST000790_1	Fuchs’s corneal dystrophy	1.000000e-06
GCST001585_17	Breast size	2.000000e-06
GCST001818_1	Metabolite levels (HVA/5-HIAA ratio)	5.000000e-06
GCST002987_17	Stroke	6.000000e-07
GCST002987_4	Stroke	6.000000e-07
GCST002988_2	Ischemic stroke	7.000000e-07
GCST002988_6	Ischemic stroke	7.000000e-07
GCST003427_161	Alzheimer disease and age of onset	4.000000e-08
GCST003518_52	Daytime sleep phenotypes	5.000000e-06
GCST003650_4	Bacteremia	1.000000e-07
GCST004001_12	Bipolar disorder or attention deficit hyperactivity disorder	8.000000e-07
GCST005231_45	Major depressive disorder	4.000000e-06
GCST008181_5	Spontaneous preterm birth without premature rupture of membranes	6.000000e-07
GCST008471_3	Non-alcoholic fatty liver disease activity score in non-alcoholic fatty liver disease	2.000000e-06
GCST008810_88	Smoking initiation (ever regular vs never regular)	8.000000e-09
GCST009391_1678	Metabolite levels	8.000000e-06
GCST009391_804	Metabolite levels	6.000000e-06
GCST010575_4	Evening vs. morning chronotype (sMEQ score)	2.000000e-06
GCST010988_147	Adult body size	9.000000e-09
GCST012226_624	Waist circumference adjusted for body mass index	4.000000e-09
GCST012226_625	Waist circumference adjusted for body mass index	3.000000e-13
GCST012490_154	Femur bone mineral density x serum urate levels interaction	1.000000e-11
GCST012490_328	Femur bone mineral density x serum urate levels interaction	2.000000e-09
GCST90020029_1037	Waist circumference adjusted for body mass index	3.000000e-11
GCST90020029_1038	Waist circumference adjusted for body mass index	3.000000e-08
GCST90020029_1039	Waist circumference adjusted for body mass index	2.000000e-13
GCST90020029_1210	Waist circumference adjusted for body mass index	1.000000e-08
GCST90020029_1211	Waist circumference adjusted for body mass index	1.000000e-12

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0004682	QT interval
EFO:0005131	HVA measurement
EFO:0005132	5-HIAA measurement
EFO:0004847	age at onset
EFO:0007828	daytime rest measurement
EFO:0006917	spontaneous preterm birth
EFO:0008421	non-alcoholic fatty liver disease severity measurement
EFO:0005670	smoking initiation
EFO:0010342	cholesteryl ester 16:1 measurement
EFO:0010396	sphingomyelin 22:1 measurement
EFO:0008328	chronotype measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0004531	urate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4905 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Receptor tyrosine phosphatase (RTP) family

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
compound 1 [PMID: 21882820]	Inhibition	5.6	pKi

Binding affinities (BindingDB)

1 measured of 2 human assays (2 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	IC50	2900 nM	US-9522881: Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)

ChEMBL bioactivities

20 potent at pChembl≥5 of 27 total, top 19 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.30	IC50	500	nM	CHEMBL1910889
5.89	IC50	1300	nM	CHEMBL1910968
5.75	IC50	1800	nM	CHEMBL2316907
5.62	IC50	2400	nM	CHEMBL3319356
5.60	IC50	2500	nM	CHEMBL1403981
5.60	Ki	2500	nM	CHEMBL1403981
5.58	IC50	2600	nM	CHEMBL2316902
5.58	IC50	2600	nM	CHEMBL1403981
5.48	IC50	3300	nM	CHEMBL1910886
5.47	IC50	3400	nM	CHEMBL1910882
5.47	IC50	3400	nM	CHEMBL1910887
5.42	IC50	3800	nM	CHEMBL1910888
5.40	IC50	4000	nM	CHEMBL2396718
5.40	IC50	4000	nM	CHEMBL1910966
5.30	IC50	5000	nM	CHEMBL2316906
5.27	IC50	5400	nM	CHEMBL1910962
5.24	IC50	5800	nM	CHEMBL1910963
5.24	IC50	5800	nM	CHEMBL1910967
5.00	IC50	1e+04	nM	CHEMBL1910965

PubChem BioAssay actives

19 with measured affinity, of 63 total; 17 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-[[3-[(3,4-dichlorophenyl)methylsulfanyl]thiophene-2-carbonyl]sulfamoyl]-2-methoxybenzoic acid	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	0.5000	uM
4-[2-[3-[(2-aminoacetyl)amino]phenyl]ethynyl]-2-[(3,4-dichlorophenyl)methylsulfanyl]benzoic acid	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	1.3000	uM
6-hydroxy-2-phenyl-3-[2-[4-(trifluoromethoxy)phenyl]ethynyl]-1-benzofuran-5-carboxylic acid	725023: Inhibition of PTPgamma (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	1.8000	uM
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	1182549: Inhibition of PTPgamma (unknown origin)	ic50	2.4000	uM
3-[(3,4-dichlorophenyl)methylsulfanyl]thiophene-2-carboxylic acid	627364: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 40 mins by FRET assay	ic50	2.5000	uM
6-hydroxy-2-phenyl-3-[2-[3-(trifluoromethyl)phenyl]ethynyl]-1-benzofuran-5-carboxylic acid	725023: Inhibition of PTPgamma (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	2.6000	uM
3-[(3,4-dichlorophenyl)methylsulfanyl]-N-methylsulfonylthiophene-2-carboxamide	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	3.3000	uM
3-[(3,4-dibromophenyl)methylsulfanyl]thiophene-2-carboxylic acid	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	3.4000	uM
N-(benzenesulfonyl)-3-[(3,4-dichlorophenyl)methylsulfanyl]thiophene-2-carboxamide	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	3.4000	uM
N-(3-aminophenyl)sulfonyl-3-[(3,4-dichlorophenyl)methylsulfanyl]thiophene-2-carboxamide	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	3.8000	uM
2-[(3,4-dichlorophenyl)methylsulfanyl]-4-(4-hydroxybut-1-ynyl)benzoic acid	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	4.0000	uM
3-[2-(3-chlorophenyl)ethynyl]-6-hydroxy-2-[4-[2-oxo-2-(propylamino)ethoxy]phenyl]-1-benzofuran-5-carboxylic acid	755766: Inhibition of recombinant PTPgamma (unknown origin) using pNPP as substrate by spectrophotometric analysis	ic50	4.0000	uM
3-[2-(3,5-difluorophenyl)ethynyl]-6-hydroxy-2-phenyl-1-benzofuran-5-carboxylic acid	725023: Inhibition of PTPgamma (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	5.0000	uM
methyl 5-[[3-[(3,4-dichlorophenyl)methylsulfanyl]thiophene-2-carbonyl]sulfamoyl]-2-methoxybenzoate	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	5.4000	uM
2-[(3,4-dichlorophenyl)methylsulfanyl]benzoic acid	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	5.8000	uM
4-[2-(3-aminophenyl)ethynyl]-2-[(3,4-dichlorophenyl)methylsulfanyl]benzoic acid	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	5.8000	uM
4-bromo-2-[(3,4-dichlorophenyl)methylsulfanyl]benzoic acid	627365: Inhibition of RPTPgamma expressed in Escherichia coli BL21 (DE3) assessed as reduction in dephosphorylation of Z’-Lyte phospho-Tyr 1 peptide preincubated for 20 mins by FRET assay	ic50	10.0000	uM

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression, increases expression	4
Benzo(a)pyrene	decreases expression, affects methylation	4
Cadmium Chloride	increases expression, decreases expression, increases abundance	4
Fulvestrant	affects cotreatment, increases methylation, decreases reaction, increases expression	2
Cadmium	decreases expression, increases abundance, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Valproic Acid	affects expression, increases expression	2
Aflatoxin B1	increases methylation	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
methylmercuric chloride	increases expression	1
bisphenol A	affects cotreatment, increases methylation	1
titanium dioxide	decreases methylation	1
terbufos	increases methylation	1
afimoxifene	increases expression, decreases reaction	1
cobaltous chloride	decreases expression	1
potassium chromate(VI)	decreases expression	1
aflatoxin B2	decreases methylation	1
nickel sulfate	decreases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
(+)-JQ1 compound	increases expression	1
Irinotecan	decreases expression	1
Resveratrol	decreases expression	1
Decitabine	affects methylation	1
Sunitinib	increases expression	1
Zoledronic Acid	increases expression	1
Leflunomide	increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Arsenic	affects methylation	1

ChEMBL screening assays

22 unique, capped per target: 21 binding, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1914000	Binding	Binding affinity to RPTPgamma expressed in Escherichia coli Rosetta (DE3) assessed as reduction in T2 relaxation curve at 50 uM by 1H/15N TROSY NMR spectroscopy	Small molecule receptor protein tyrosine phosphatase γ (RPTPγ) ligands that inhibit phosphatase activity via perturbation of the tryptophan-proline-aspartate (WPD) loop. — J Med Chem
CHEMBL4626317	ADMET	Inhibition of PTPG (unknown origin) expressed in Escherichia coli BL21 using p-nitrophenyl phosphate as substrate measured after 30 mins by UV-vis spectrophotometric method	Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.